July 28th, 2011
When Will Palliative Care and Hospice Discussions Be Considered Normal?
Heather M Johnson, MD, MS
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog, Dr John M.
The patient greeted me with a smile that belied his horrible luck. He was my age but looked far older.
It was a slowly progressive neurological disorder that left his mind intact while his body stopped working. He was now imprisoned in a bed. Various family members fed him, changed his diaper, and freshened the skin bandages on his legs — “road rash” that recurred after repeated falls. He refused to stop trying to get OOB — out of bed. He had his pride.
The immobility caused problems with his urinary tract. Kidney stones kept getting infected by bacteria, which traveled up and around that permanent rubber tube in his bladder. Surgery to remove the stones was recommended.
But that dang ECG was a problem. It showed a high heart rate; 160 beats per minute was high enough to excite most of the medical people on his case. Though he reported no heart-related symptoms, he did indeed have a common, benign, non-life-threatening heart rhythm condition called PSVT, or paroxysmal supraventricular tachycardia. It occurs because of an extra electrical highway that one is born with. The two pathways conspire to cause the heart to spontaneously race. It, too, occurs because of bad luck, and in this case was unrelated to the neurological condition.
I was called in to consider fixing the racing heart. On paper, a catheter ablation for PSVT is straightforward. However, this case was a problem. His chronic illness conferred a higher than normal risk:
- Pneumonia as a complication from sedation;
- Blood clots in the legs from immobility after the procedure;
- Contracted arms across his chest, making X-ray visualization of his heart a challenge.
Now these were not insurmountable problems. A catheter ablation could be done, and likely with success. Sure, the master-of-the-obvious EP-lab nurses might have looked askance because I was ablating a patient in diapers, but I could have offered them a lame excuse, like referring-doctor X is making me do it, so it’s not my idea, or the patient had to have it before kidney surgery.
The larger issue at hand, however, was that the patient needed something else. He needed someone to tell him the truth, to mention the large elephant in the room — that he had a diaper, bedsores, and a progressive neurological condition. When your lifespan is measured in weeks or months, elective ablation for a non-symptomatic, benign heart condition makes little sense.
When I discussed his heart with another subspecialist on the case, I voiced my opinion that doing an ablation was not indicated. I added that his medical problems and lack of any significant functional capacity warranted consideration of hospice.
“Yes, I get that, but what was I to do: Tell him…Nice to meet you sir… I have only known you for ten minutes, but really, you only have weeks to months to live. We should have hospice come to see you.”
That’s the thing. Just mentioning hospice is like holding a hot potato. For instance, when I suggested a hospice consultation to one of the younger health professionals involved with this patient’s care, she looked at me sideways, as if to say “People don’t really die. We can prevent death here in this ICU. We have protocols, and respirators, and pressors.” Geez.
And consider this fact: As our health care is increasingly fragmented, between out- and inpatient services, the problem of bringing up hospice and palliative care intensifies. In general, subspecialists called to see a patient for problems of their specific organs are not going to start the palliative care discussion. We don’t know how. We are not trained to consider death as inevitable. More than a few heart doctors I know consider death to be a failure of therapy. A mistake. If only we had titrated the drugs more skillfully, implanted an ICD, or squished the blockage sooner.
The health care profession needs a culture change. We need hospice and palliative care to be a normal option, not one that is given ten minutes before death. The control of symptoms, rather than the prolongation of life at all costs, should be mentioned without stigma. I’d even go so far as to make the “goals of care” discussion part of a checklist. Just make the conversation as “normal” as taking a statin or an ACE inhibitor, or calling a time out. Make it normal for patients to hear that relief of symptoms is as viable a choice as eking out the maximum number of days with toxic drugs or painful procedures.
I found it heartening to read this Washington Post story on how some emergency rooms benefit from having palliative care teams available. That’s a step in the right direction. But there’s a lot of work left to be done in the real world.
In this heart-wrenching case, I spoke with the patient, the nurse, the family (multiple times), and the two other doctors on the case. In total, I spent two to three times longer than it would have taken for me to ablate the heart problem, and I was paid many-fold less for the emotionally draining work.
This is a problem…
One I hope to see corrected soon.
JMM
P.S. This case occurred many months ago, when I worked at many different hospitals. I have changed the details to maintain privacy.
July 28th, 2011
AstraZeneca Sets Premium Price for Ticagrelor
Larry Husten, PHD
AstraZeneca will be charging a premium price for its new antiplatelet drug ticagrelor (Brilinta). Wall Street analyst Timothy Anderson reports that the daily treatment cost for the drug will be $7.24 on a wholesaler acquisition cost (WAC) basis, which is approximately 20% higher than the daily cost of $6.08 for clopidogrel (Plavix) and about 25% higher than the daily cost of $5.78 for prasugrel (Effient). AstraZeneca issued the following statement about the price:
“Brilinta will be priced to reflect the label and its value in treating patients with ACS. AstraZeneca believes Brilinta should be priced at a premium because of its label and the safety and efficacy versus clopidogrel. The cost to an individual patient will differ depending on an individual patient’s health insurance status. As with all of our medicines, we want to help make sure that the people who are prescribed Brilinta have access to it.”
Sorry, there are no polls available at the moment.
July 26th, 2011
Coronary and Cerebrovascular Disease May Differ in Their Heritability
Larry Husten, PHD
Although coronary and cerebrovascular disease usually receive equal weight when family history is assessed as a risk factor, a new study suggests that family history may play a more important role in MI and ACS than in stroke or TIA.
In an article published in Circulation: Cardiovascular Genetics, Amitava Banerjee and colleagues report the results of a population-based study in which they assessed the relative heritability of cerebral and coronary events in 906 patients with ACS and 1015 patients with cerebrovascular disease. For the ACS patients, parental MI was strongly associated with MI in one or more siblings:
- 1 parent with MI: odds ratio, 1.48; 95% CI, 1.04-2.10; P=0.03
- 2 parents with MI: OR, 5.97; 95% CI, 3.23-11.03; P<0.0001
For the stroke and TIA patients, the association of parental stroke with sibling stroke did not achieve statistical significance:
- 1 parent with stroke: OR, 0.88; 95% CI, 0.50-1.56; P=0.67
- 2 parents with stroke: OR, 1.19; 95% CI, 0.27-5.29; P=0.81
In all, 142 ACS cases (15.7%) occurred in families in which 2 or more first-degree relatives were also affected. By contrast, only 56 (5.1%) of patients with TIA or stroke occurred in families in which 2 or more first-degree relatives were also affected.
In an AHA press release, senior author Peter Rothwell said that “the way physicians predict the odds of a healthy person suffering a heart attack or stroke needs refining. Currently, most risk models lump a patient’s family history of stroke and heart attack together. We probably should model family history of stroke and heart attack separately in the future.”
July 25th, 2011
Panel: Will You Prescribe Ticagrelor (Brilinta)?
CardioExchange Editors, Staff
The FDA recently approved ticagrelor (Brilinta) to reduce cardiovascular death and MI in patients with acute coronary syndromes. The drug’s label will include a boxed warning about bleeding risks and will state that aspirin doses greater than 100 mg/day decrease the drug’s efficacy. We asked a panel of experts this question:
Will you prescribe ticagrelor? If so, to which patients? If not, why not?
David Cohen (Saint Luke’s, Kansas City): I think that ticagrelor will play a role in my clinical practice. The main advantage of ticagrelor over other available oral antiplatelet drugs (clopidogrel and prasugrel) is its relative reversibility and comparatively shorter biologic half-life. Accordingly, I think the main group of patients I will treat with ticagrelor are those who present with non–ST-elevation ACS who are being seen “upstream” prior to cardiac catheterization or for whom conservative therapy (rather than an invasive strategy) is chosen. The decision about which agent to continue after an invasively managed patient undergoes PCI will need to be individualized, taking into account multiple factors including bleeding risk, affordability (including insurance coverage), and the patient’s ability to comply reliably with a twice-daily regimen.
David Moliterno (U. Kentucky): We will definitely be using ticagrelor at the University of Kentucky. It is a terrific new agent for ischemic heart disease, but with remaining important questions regarding its real-world application — which patients, when, and for how long? Like many place throughout the U.S. healthcare market, we have practical limitations regarding cost, compliance, and concomitant medications.
Jeffrey Trost (Johns Hopkins): I would prescribe ticagrelor, based on the strength of the clinical efficacy data of the PLATO trial, to patients with acute coronary syndrome. It is hard to ignore the relative reductions in mortality, recurrent myocardial infarction, and stent thrombosis that favor ticagrelor, with equivalent safety to clopidogrel in terms of bleeding. However, aside from efficacy and safety, what patients care about most is ease of use and cost, and ticagrelor is inferior to clopidogrel on both counts. As a twice-daily drug with a higher cost than once-daily clopidogrel, I won’t be prescribing this drug to patients who have difficulty affording their medications or difficulty taking medications at all. I certainly will tell these patients why I think ticagrelor is better, but I will also understand if they prefer a cheaper, once-daily alternative. I will be prescribing this drug to patients who are willing to take a twice-daily drug and are comfortable with the cost of taking it.
Take our poll. Then explain your answer as a comment below:
Sorry, there are no polls available at the moment.
July 25th, 2011
Adding HbA1c Measurements Improves CV Risk Prediction in Diabetics
Larry Husten, PHD
Current risk prediction models classify diabetes as equivalent to established cardiovascular disease. Now, a new report from the Women’s Health Study and the Physician’s Health Study II suggests that adding HbA1c measurements to the model can improve risk prediction and lead to downward classification of some diabetics.
In a paper published in Archives of Internal Medicine, Nina Paynter and colleagues analyzed data from 24,674 women and 11,280 men (685 women and 563 men were diabetic at baseline). Cardiovascular events occurred in 125 diabetic women and 170 diabetic men. In women, including HbA1c levels improved the C statistic by 0.177 (P<0.001) and improved the accuracy of the risk-category assignment. The results were less dramatic in men, but the C statistic improved by 0.039 (P<0.02), and the accuracy of the risk-category assignment also improved.
The authors note that the presence of diabetes by itself did not indicate a 10-year CV risk greater than 20% for all patients, implying that their findings “are consistent with previously published studies suggesting that not all diabetic patients are at high risk of future vascular events.” They point out that their “results may be particularly helpful in light of current discussion around treatment choices for diabetic patients for prevention of CVD, including use of statins and aspirin.”
In an accompanying comment, Mark Pletcher writes that “there is little doubt that the primary findings” of the study are true, and that using HbA1c measurements would allow downward reclassification of some diabetic patients. However, he questions whether this will result in actual health benefits. Noting that diabetics have a substantially elevated lifetime risk for CV events, he asks: “Will it really benefit diabetic persons with low or medium short-term risk to withhold statins?”
July 24th, 2011
APPRAISE-2 Dashes Hope of Adding Anticoagulant to Antiplatelet Therapy in ACS
Larry Husten, PHD
The factor Xa inhibitor apixaban (under joint development by Bristol Myers Squibb and Pfizer as Eliquis) has been the subject of intense interest in recent years, showing great promise for thromboprophylaxis after surgery and for stroke prevention in AF. Some pundits now believe apixaban will become the anticoagulant of choice for the AF indication, although the basis for this is only a press release about the ARISTOTLE trial, which has not yet been presented or published. So far the only major disappointment concerning the drug has been the APPRAISE-2 trial in ACS patients, which was terminated early last November. The results of the trial have now been presented at the International Society on Thrombosis and Haemostasis Congress in Kyoto and published in the New England Journal of Medicine.
APPRAISE-2 (Apixaban for Prevention of Acute Ischemic Events–2) was a phase 3 trial comparing apixaban with placebo in patients with acute coronary syndrome (ACS) who were already receiving standard antiplatelet therapy and who had at least 2 additional risk factors for recurrent ischemic events. The trial was stopped early after 7392 patients had been enrolled (of 10,800 initially planned) due to an increase in major bleeding events among apixaban recipients.
Here are the main results of the trial, after a median follow-up of 241 days:
Primary endpoint (combined rate of cardiovascular death, MI, or ischemic stroke):
- 7.5% (279/3705) in the apixaban group versus 7.9% (293/3687) in the placebo group
- hazard ratio with apixaban:0.95 (95% CI, 0.80-1.11; P=0.51)
Major bleeding:
- 1.3% (46/3673) in the apixaban group versus 0.5% (18/3642) in the placebo group
- hazard ratio with apixaban: 2.59 (95% CI, 1.50-4.46; P=0.001)
The authors write that the results of APPRAISE-2 fail to confirm the hope derived from three phase 2 trials suggesting that oral anticoagulants when added to antiplatelet therapy in ACS patients would reduce recurrent events but would not cause a large excess of bleeding complications. The results of the trial, they write, “raise doubt about whether meaningful incremental efficacy can be achieved with an acceptable risk of bleeding by combining a long-term oral anticoagulant with both aspirin and a P2Y12-receptor antagonist in patients with coronary disease.”
July 21st, 2011
FDA and EMA Issue Updates on Dronedarone, Varenicline, and Pioglitazone
Larry Husten, PHD
The FDA has issued an update on dronedarone (Multaq, Sanofi Aventis), and the European Medicines Agency (EMA) has updated its reviews of dronedarone and 2 other drugs that also have been the subject of recent controversies: pioglitazone (Actos and other names, Takeda) and varenicline (Champix, Pfizer).
The FDA and dronedarone: The FDA issued a safety communication about dronedarone and an increased risk for death and serious CV events. The agency said it was reviewing data from the PALLAS (Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy) trial, which Sanofi announced on July 7 had been prematurely stopped. The PALLAS trial was testing the effect of dronedarone in patients with permanent AF, which is not an indication for dronedarone currently. According to the FDA:
A critical question is whether and how the unfavorable results of the PALLAS study, obtained in patients with permanent atrial fibrillation, apply to patients who use Multaq for the approved indications (non-permanent atrial fibrillation, also known as paroxysmal or persistent atrial fibrillation).
The FDA did not recommend that patients stop taking dronedarone but did recommend that they “should talk to their healthcare professional about whether they should continue to take Multaq for non-permanent atrial fibrillation.”
Dronedarone was the subject of a safety warning earlier this year based on reports of rare but severe cases of liver injury.
Here is the table of events released by the FDA (click to enlarge):
Separately, the EMA issued 3 separate updates about dronedarone, varenicline, and pioglitazone.
Dronedarone: The EMA said it was reviewing the benefits and risk of dronedarone based on the PALLAS data, and that the new data “could have an impact on the use of the medicine in its approved indication.” The EMA advised prescribers “to monitor patients regularly in order to ensure that they remain within the authorized indication and do not progress to permanent atrial fibrillation.”
The EMA noted that the Committee for Medicinal Products for Human Use (CHMP), which had already initiated a review of dronedarone based on the reports of severe liver injury, would extend its review of the drug until September 2011, when it will issue a final assessment.
Varenicline: The EMA confirmed the “positive benefit-risk balance” of varenicline, saying that its “benefits as a smoking-cessation medicine outweigh a slight reported increase in cardiovascular events.” Earlier this year, on June 16, the FDA issued its own warning on this subject based on a meta-analysis that was subsequently published on July 4 in the Canadian Medical Association Journal. CHMP said it had “identified a number of limitations of the meta-analysis, including the low number of events seen, the types of events counted, the higher drop-out rates in people receiving placebo, the lack of information on the timing of events, and the exclusion of studies in which no one had an event. Because of these limitations, the Committee could not draw robust conclusions from the meta-analysis.” CHMP said it will conduct an expedited review of an application to update varenicline’s product information and is aiming to offer a recommendation in September 2011.
Pioglitazone: The EMA said that CHMP had finished its review of pioglitazone and that “there is a small increased risk of bladder cancer in patients taking” medicines that contain pioglitazone. Nevertheless, it “confirmed that these medicines remain a valid treatment option for certain patients with type 2 diabetes.” CHMP said that the small increased risk of bladder cancer “could be reduced by appropriate patient selection and exclusion, including a requirement for periodic review of the efficacy and safety of the individual patient’s treatment.”
July 21st, 2011
Carotid IMT Provides Modest Improvement to Risk Prediction
Larry Husten, PHD
Measurement of the maximum intima–media thickness (IMT) of the internal carotid artery (CA) can modestly improve cardiovascular risk prediction, according to a new study published in the New England Journal of Medicine. Joseph Polak and colleagues measured the mean IMT of the common CA and the maximum IMT of the internal CA of 2965 subjects taking part in the Framingham Offspring Study. The subjects were then followed for a mean of 7.2 years, and the value of adding IMT measurements to the Framingham Risk Score (FRS) was assessed.
Although adding the mean IMT of the common CA did not significantly improve risk prediction, the hazard ratio for a 1 standard-deviation increase in the maximum IMT of the internal CA was 1.21 (95% CI, 1.13-1.29), along with an increase in the C statistic that the authors called “modest” (0.009; 95% CI, 0.003-0.016). The use of maximum IMT of the internal CA also improved the assignment of the low-, intermediate-, or high-FRS categories, as measured by the net reclassification index. Finally, the presence of plaque greater than 1.5 mm in the IMT of the internal CA also improved the predictive power of the FRS.
In their discussion, the authors write that their results should have an impact on the current ACCF-AHA guidelines for primary prevention, as the current level IIa recommendation lacks a quantitative basis. They conclude that maximum IMT of the internal CA contributes “significantly but modestly to the predictive power of the risk factors used in calculating the Framingham risk score.”
July 21st, 2011
Sapien Transcatheter Heart Valve Receives Strong Support from FDA Advisory Panel
Larry Husten, PHD
The FDA Circulatory Systems Devices Panel has given a strong vote of support in favor of the Sapien Transcatheter Heart Valve (THV) for use in patients with inoperable severe aortic stenosis and with no comorbidities precluding benefit from correction of the stenosis. By large majorities, the panel voted that the procedure was safe (7-3), that the procedure was effective (9-1), and that the benefits of the device outweighed the risks (9-0, 1 abstention).
During the course of the meeting, the FDA and panel members expressed a fair amount of concern that excessive enthusiasm for the device might cause a stampede of early usage. Panel members were concerned that the device might be used in patients who were not ideal candidates and by operators and centers who lacked sufficient experience.
Panel member and CardioExchange interventional cardiology blogger Rick Lange said that the committee strongly recommended that the FDA require all centers that utilize the Sapien THV to participate in a registry that would be jointly managed by the Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC) and that would include all patients who receive the device.
The committee also expressed anguish over the issue of strokes in the trial, spending much time discussing the various definitions of stroke used in PARTNER B and discrepancies between analyses of the trial from the trial’s sponsor, Edwards, and those from the FDA’s analysts.